VolitionRx Limited (VNRX)
| Market Cap | 4.75M -92.6% |
| Revenue (ttm) | 2.47M +88.5% |
| Net Income | -24.60M |
| EPS | -4.20 |
| Shares Out | 8.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 736,922 |
| Open | 0.6200 |
| Previous Close | 0.6306 |
| Day's Range | 0.5420 - 0.6300 |
| 52-Week Range | 0.5497 - 15.1000 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 16.97 (+2,877.72%) |
| Earnings Date | Aug 13, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c... [Read more]
Financial Performance
In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $16.97, which is an increase of 2,877.72% from the latest price.
News
VolitionRx Earnings Call Transcript: Q2 2026
Clinical and commercial progress continued across all product lines, with breakthroughs in sepsis and cancer diagnostics, strong licensing activity, and a 112% year-over-year revenue increase for the first half. Operating expenses fell 32% year-over-year, but revenue remains lumpy due to project timing.
VolitionRx Earnings release: Q2 2026
VolitionRx released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q2 2026
VolitionRx has published its Q2 2026 quarterly earnings report on August 14, 2026.
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), ...
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx...
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
VolitionRx registers to sell 3.31M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.31M shares of common stock. The company is not selling any…
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
VolitionRx announces data on prognostic value of Nu.Q Cancer Assay
VolitionRx (VNRX) announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q Cancer Assay in newly diagnosed lung cancer patients, which could help clinic...
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstra...
VolitionRx resumed with a Buy at Maxim
Maxim resumed coverage of VolitionRx (VNRX) with a Buy rating and $4 price target The company is on track for significant progress across its diagnostic portfolio, including its core franchises:…
VolitionRx announces collaboration with Sysmex
VolitionRx (VNRX) announces a collaboration with Sysmex, a leader in global in vitro diagnostics, to optimize Volition’s Nu.Q NETs H3.1 assay on the Sysmex platform.
VolitionRx Announces Collaboration with Sysmex
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader ...
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NY...
VolitionRx files patent covering Nu.Q technology for Ebola triage
VolitionRx (VNRX) announces that it has expanded its intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monito...
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics co...
VolitionRx Proxy statement: Proxy filing
VolitionRx filed a proxy statement on June 2, 2026, providing details for shareholder voting and corporate governance matters.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., May 27, 202...
VolitionRx Earnings Call Transcript: Q1 2026
Revenue surged 300% year-over-year to $1 million, driven by deferred revenue from the Nu.Q Vet agreement, while operating expenses rose due to R&D and severance costs. Major product milestones included validation of the feline cancer assay and advances in liquid biopsy technology.
VolitionRx Earnings release: Q1 2026
VolitionRx released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q1 2026
VolitionRx has published its Q1 2026 quarterly earnings report on May 15, 2026.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.